FPA144: Additional Phase I data

Data from 9 patients with FGFR2b-positive gastric cancer in the dose-escalation Part 1 of an open-label, international Phase I trial showed that 6-15 mg/kg IV FPA144 every 2 weeks led to an ORR of 33%...